MULTISYSTEM ADVERSE EFFECTS OF ISOTRETINOIN: MECHANISTIC INSIGHTS AND CLINICAL IMPLICATIONS
Abstract
Isotretinoin (13-cis-retinoic acid) remains the most effective systemic therapy for severe acne, exerting its therapeutic action through modulation of retinoic acid (RAR) and retinoid X (RXR) receptors that regulate cell differentiation, apoptosis, and lipid metabolism. However, these same receptor-mediated pathways underlie a range of multisystem adverse effects. This review provides an updated synthesis of isotretinoin’s systemic toxicity profile, focusing on mechanistic insights and clinical relevance. Mucocutaneous reactions such as cheilitis and xerosis are the most frequent and predictable effects, reflecting sebaceous suppression. Hepatic enzyme elevations and dyslipidemia occur in a dose-dependent yet reversible manner, necessitating routine laboratory surveillance. Musculoskeletal, ocular, and neuropsychiatric effects are infrequent, generally mild, and self-limiting, though psychiatric monitoring remains advisable in predisposed individuals. Gastrointestinal and endocrine disturbances, including subclinical hypothyroidism, have been reported but lack strong causal evidence. Hematologic and renal alterations are minor and transient. The most critical safety concern remains isotretinoin’s potent teratogenicity, emphasizing the need for strict contraceptive protocols and post-therapy washout periods. Overall, isotretinoin’s adverse effects largely reflect its pharmacodynamic actions and are manageable through individualized dosing and systematic monitoring. Understanding the mechanisms and risk factors underlying these reactions is essential for optimizing therapeutic safety and patient outcomes.
References
Reynolds, R. V., Yeung, H., Cheng, C. E., Cook-Bolden, F., Desai, S. R., Druby, K. M., Freeman, E. E., Keri, J. E., Stein Gold, L. F., Tan, J. K. L., Tollefson, M. M., Weiss, J. S., Wu, P. A., Zaenglein, A. L., Han, J. M., & Barbieri, J. S. (2024). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 90(5), 1006.e1–1006.e30. https://doi.org/10.1016/j.jaad.2023.12.017
Nofal, A., Hussein, G.H., Ahmed, N., & Ibrahim, A.S. (2024). Inflammatory biomarkers and clinical adverse effects associated with Isotretinoin treatment: A prospective study. Egyptian Journal of Dermatology and Venereology.
Bagatin, E., & Costa, C. S. (2020). The use of isotretinoin for acne - an update on optimal dosing, surveillance, and adverse effects. Expert review of clinical pharmacology, 13(8), 885–897. https://doi.org/10.1080/17512433.2020.1796637
Sanjel, K., & Zhang, X. (2022). Progress of different treatment modalities to limit the use of antibiotics in the treatment of acne. Our Dermatology Online, 13, 92–97. https://doi.org/10.7241/ourd.20221.23
Melnik B. C. (2023). Acne Transcriptomics: Fundamentals of Acne Pathogenesis and Isotretinoin Treatment. Cells, 12(22), 2600. https://doi.org/10.3390/cells12222600
Tan, T. H., Hallett, R., & Yesudian, P. D. (2016). Efficacy and relapse rates of different Isotretinoin dosages in treating acne vulgaris: systemic review. Clinical medicine (London, England), 16 Suppl 3(Suppl 3), s34. https://doi.org/10.7861/clinmedicine.16-3-s34
Ünlü Açıkel, S., & Sadettin Burak, A. (2025). Bibliometric analysis of studies investigating the association between isotretinoin use and depression and suicide. Clinical and experimental dermatology, llae395. Advance online publication. https://doi.org/10.1093/ced/llae395
Uysal, P. I. (2021). Rapid-onset oral isotretinoin-induced acne fulminans without systemic symptoms in a male adolescent. Our Dermatology Online, 12(4), 417–418.
Yao, Q. H., & Liu, Z. H. (2024). Rosacea Fulminans in Pregnancy: A Case Report and Review. Clinical, cosmetic and investigational dermatology, 17, 1999–2007. https://doi.org/10.2147/CCID.S481939.
Mahsoub, N. I. I., Elsohafy, M. A., Hasan, A. M., & Ismael, A. F. (2024). Most common isotretinoin therapy side effects on Egyptian acne females in Dakahlia Governorate. The Egyptian Journal of Hospital Medicine, 96, 2860–2870.
Topal, İ. O., & Otunctemur, A. (2020). An investigation of the effects of acitretin on erectile function. Our Dermatology Online, 11(Suppl. S3), 1–5.
Kouotou, E. A., Nguena Feungue, U., Tounouga, D. N., Ngoune Madjoukeng, A. S., Nkoro, G. A., Sigha, B. O., Ekambi, R. K., & Zoung-Kanyi Bissek, A. C. (2023). Severity of acne and quality of life of patients treated at Cameroonian hospitals (sub-Saharan Africa). Our Dermatology Online, 14, 16–22. https://doi.org/10.7241/ourd.20231.4
Alghamdi, W. A., Alwesaibie, H. S., Albesher, M. A., Alghamdi, F. K., & Albaqshi, A. A. (2023). Knowledge, Attitude, and Practice Regarding the Use of Isotretinoin in Saudi Arabia. Cureus, 15(12), e50516. https://doi.org/10.7759/cureus.50516
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., Keri, J. E., Leyden, J. J., Reynolds, R. V., Silverberg, N. B., Stein Gold, L. F., Tollefson, M. M., Weiss, J. S., Dolan, N. C., Sagan, A. A., Stern, M., … Bhushan, R. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945–73.e33. https://doi.org/10.1016/j.jaad.2015.12.037.
Sarkar, T., Sarkar, S., & Patra, A. (2018). Low-dose isotretinoin therapy and blood lipid abnormality: A case series with sixty patients. Journal of family medicine and primary care, 7(1), 171–174. https://doi.org/10.4103/jfmpc.jfmpc_104_16
Kızılyel, O., Metin, M. S., Elmas, Ö. F., Çayır, Y., & Aktaş, A. (2014). Effects of oral isotretinoin on lipids and liver enzymes in acne patients. Cutis, 94(5), 234–238..
Zech, L. A., Gross, E. G., Peck, G. L., & Brewer, H. B. (1983). Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study. Archives of dermatology, 119(12), 987–993.
O'Leary, T. J., Simo, I. E., Kanigsberg, N., Walker, J., Goodall, J. C., & Ooi, T. C. (1987). Changes in serum lipoproteins and high-density lipoprotein composition during isotretinoin therapy. Clinical and investigative medicine. Medecine clinique et experimentale, 10(4), 355–360.
Rodondi, N., Darioli, R., Ramelet, A. A., Hohl, D., Lenain, V., Perdrix, J., Wietlisbach, V., Riesen, W. F., Walther, T., Medinger, L., Nicod, P., Desvergne, B., & Mooser, V. (2002). High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: a pharmacogenetic study. Annals of internal medicine, 136(8), 582–589. https://doi.org/10.7326/0003-4819-136-8-200204160-00007
Peck, G. L., Olsen, T. G., Yoder, F. W., Strauss, J. S., Downing, D. T., Pandya, M., Butkus, D., & Arnaud-Battandier, J. (1979). Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. The New England journal of medicine, 300(7), 329–333. https://doi.org/10.1056/NEJM197902153000701
Rademaker M. (2013). Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us?. The Australasian journal of dermatology, 54(3), 157–162. https://doi.org/10.1111/j.1440-0960.2012.00947.x
Almarri, F. H., Al Dhafiri, M., Albejais, R. A., Albaqshi, M. A., & Alotaibi, W. D. (2024). The Perception of Contraceptive Practice Among Female Patients Treated With Isotretinoin in Saudi Arabia. Cureus, 16(9), e69390. https://doi.org/10.7759/cureus.69390
Al-Sheyab, R. F., Alshiyab, D., Al-Shagarin, R. A., Murshidi, R., ALSalamat, H. A., Abu-Rayyan, H., Abu-Arja, Y., Ghunaim, S., & Altamimi, S. (2024). Prescribing Patterns of Isotretinoin for Acne Among Dermatologists in Central Jordan. Cureus, 16(4), e58840. https://doi.org/10.7759/cureus.58840.
Bagatin, E., Costa, C. S., Rocha, M. A. D. D., Picosse, F. R., Kamamoto, C. S. L., Pirmez, R., Ianhez, M., & Miot, H. A. (2020). Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology. Anais brasileiros de dermatologia, 95 Suppl 1(Suppl 1), 19–38. https://doi.org/10.1016/j.abd.2020.09.001
Roos, T. C., Jugert, F. K., Merk, H. F., & Bickers, D. R. (1998). Retinoid metabolism in the skin. Pharmacological reviews, 50(2), 315–333..
Melnik B. C. (2017). Apoptosis May Explain the Pharmacological Mode of Action and Adverse Effects of Isotretinoin, Including Teratogenicity. Acta dermato-venereologica, 97(2), 173–181. https://doi.org/10.2340/00015555-2535
Zouboulis C. C. (2006). Isotretinoin revisited: pluripotent effects on human sebaceous gland cells. The Journal of investigative dermatology, 126(10), 2154–2156. https://doi.org/10.1038/sj.jid.5700418
Agamia, N. F., El Mulla, K. F., Alsayed, N. M., Ghazala, R. M., El Maksoud, R. E. A., Abdelmeniem, I. M., Talaat, I. M., Zaki, I. I., Sabah, R. M., & Melnik, B. C. (2023). Isotretinoin treatment upregulates the expression of p53 in the skin and sebaceous glands of patients with acne vulgaris. Archives of dermatological research, 315(5), 1355–1365. https://doi.org/10.1007/s00403-022-02508-y
Orfanos, C. E., Zouboulis, C. C., Almond-Roesler, B., & Geilen, C. C. (1997). Current use and future potential role of retinoids in dermatology. Drugs, 53(3), 358–388. https://doi.org/10.2165/00003495-199753030-00003
Karlsson, T., Vahlquist, A., Kedishvili, N., & Törmä, H. (2003). 13-cis-retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands?. Biochemical and biophysical research communications, 303(1), 273–278. https://doi.org/10.1016/s0006-291x(03)00332-2
Holland, D. B., Jeremy, A. H., Roberts, S. G., Seukeran, D. C., Layton, A. M., & Cunliffe, W. J. (2004). Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. The British journal of dermatology, 150(1), 72–81. https://doi.org/10.1111/j.1365-2133.2004.05749.x
Saber, M., Bahraminejad, M., Fatemi Naeini, F., Mohaghegh, F., Faghihi, G., & Hosseini, S. M. (2022). Comparison of systemic and topical isotretinoin in the treatment of facial lichen planopilaris: A randomized controlled trial. Journal of cosmetic dermatology, 21(9), 3896–3904. https://doi.org/10.1111/jocd.14730.
Li, Y., Xia, J., Zhu, Y., He, S., Liu, J., Zeng, W., & Wang, Z. (2022). Efficacy and safety of low-level light therapy by delicate pulsed light combined with low-dose oral isotretinoin for the treatment of acne vulgaris: a randomized split-face study. Lasers in medical science, 37(8), 3221–3229. https://doi.org/10.1007/s10103-022-03606-z.
Costa, C. S., Bagatin, E., Martimbianco, A. L. C., da Silva, E. M., Lúcio, M. M., Magin, P., & Riera, R. (2018). Oral isotretinoin for acne. The Cochrane database of systematic reviews, 11(11), CD009435. https://doi.org/10.1002/14651858.CD009435.pub2.
İslamoğlu, Z. G. K., & Altınyazar, H. C. (2019). Effects of isotretinoin on the hair cycle. Journal of cosmetic dermatology, 18(2), 647–651. https://doi.org/10.1111/jocd.12800
Gencebay, G., Aşkın, Ö., & Serdaroğlu, S. (2021). Evaluation of the changes in sebum, moisturization and elasticity in acne vulgaris patients receiving systemic isotretinoin treatment. Cutaneous and ocular toxicology, 40(2), 140–144. https://doi.org/10.1080/15569527.2021.1922434.
Al Dhafiri, M., Kaliyadan, F., Almukhaimar, S., Alsultan, F., Al Hayim, E., Alnaim, R., & Aldossari, A. (2023). Isotretinoin Use and Liver Enzymes Changes: A Single-Center Study in Saudi Arabia. Cureus, 15(12), e51263. https://doi.org/10.7759/cureus.51263
Soutou, B., Sleiman, J., Tomb, R., Kechichian, E., & Helou, J. (2023). Prevalence of adverse events varies with the different oral isotretinoin brands in acne treatment: a retrospective observational study. Archives of dermatological research, 315(6), 1533–1539. https://doi.org/10.1007/s00403-023-02532-6
Kaźmierska, A., Bolesławska, I., Jagielski, P., Polańska, A., Dańczak-Pazdrowska, A., Kosewski, G., Adamski, Z., & Przysławski, J. (2022). Effect of Evening Primrose Oil Supplementation on Biochemical Parameters and Nutrition of Patients Treated with Isotretinoin for Acne Vulgaris: A Randomized Double-Blind Trial. Nutrients, 14(7), 1342. https://doi.org/10.3390/nu14071342
Dr. K. Radha Raja Prabha, Dr. S. Karthik Raja, Dr. Misbah Dulvi, & Dr. V.U. Karthikeyan. (2024). RISK OF DEPRESSION AND SUICIDAL BEHAVIOUR IN ACNE PATIENTS TREATED WITH ISOTRETINOIN: A SYSTEMATIC REVIEW AND META-ANALYSIS. Journal of Population Therapeutics and Clinical Pharmacology, 31(3), 2233-2243. https://doi.org/10.53555/jptcp.v31i3.5302
Huang, Y. C., & Cheng, Y. C. (2017). Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 76(6), 1068–1076.e9. https://doi.org/10.1016/j.jaad.2016.12.028
Botsali, A., Kocyigit, P., Professor, & Uran, P. (2020). The effects of isotretinoin on affective and cognitive functions are disparate in adolescent acne vulgaris patients. The Journal of dermatological treatment, 31(7), 734–738. https://doi.org/10.1080/09546634.2019.1606396
Fraunfelder, F. T., Fraunfelder, F. W., & Edwards, R. (2001). Ocular side effects possibly associated with isotretinoin usage. American journal of ophthalmology, 132(3), 299–305. https://doi.org/10.1016/s0002-9394(01)01024-8
Polat, M., & Kükner, Ş. (2017). The effect of oral isotretinoin on visual contrast sensitivity and amount of lacrimation in patients with acne vulgaris. Cutaneous and ocular toxicology, 36(1), 35–38. https://doi.org/10.3109/15569527.2016.1141419
Yavuz, C., & Ozcimen, M. (2019). An evaluation of peripapillar choroidal thickness in patients receiving systemic isotretinoin treatment. Cutaneous and ocular toxicology, 38(1), 25–28. https://doi.org/10.1080/15569527.2018.1503289
Almutairi, R. R., Almutairi, A. G., Alhallafi, A. F., Almudawi, N. A., AlSulaiman, M. A., Shadid, A. M., & Alharxithy, R. (2024). Isotretinoin musculoskeletahl side effects: a systematic review. Dermatology reports, 16(4), 9845. https://doi.org/10.4081/dr.2024.9845
Alkan, S., Kayiran, N., Zengin, O., Kalem, A., Kimyon, G., Kilinc, E. O., Pehlivan, Y., Kirtak, N., Onat, A. M., & Kisacik, B. (2015). Isotretinoin-induced Spondyloarthropathy-related Symptoms: A Prospective Study. The Journal of rheumatology, 42(11), 2106–2109. https://doi.org/10.3899/jrheum.150013
Yesilkaya, B., Alli, N., Artuz, R. F., Ulu, E., Kartal, D., & Cinar, S. L. (2017). The frequency of hematuria in acne vulgaris patients during isotretinoin treatment. Cutaneous and ocular toxicology, 36(1), 74–76. https://doi.org/10.3109/15569527.2016.1155595
Miqdad, M. A., Alatta, L., Abdelsamad, A., Fouda, S., Cherukuri, A. S. S., Eltanany, M., Albogami, F., Al Draiweesh, S., & Abdelrahman, N. (2022). Isotretinoin-Induced Inflammatory Bowel Disease: Is There a Real Association?. Cureus, 14(10), e29825. https://doi.org/10.7759/cureus.29825
Dhattarwal, N., Khunger, N., & Lal, A. (2022). Isotretinoin Induced Pancreatitis: A Rare Idiosyncratic Reaction. Indian journal of dermatology, 67(6), 781–783. https://doi.org/10.4103/ijd.ijd_206_22
Lee, S. Y., Jamal, M. M., Nguyen, E. T., Bechtold, M. L., & Nguyen, D. L. (2016). Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis. European journal of gastroenterology & hepatology, 28(2), 210–216. https://doi.org/10.1097/MEG.0000000000000496
Kapała, J., Lewandowska, J., Placek, W., & Owczarczyk-Saczonek, A. (2022). Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis. International journal of environmental research and public health, 19(11), 6463. https://doi.org/10.3390/ijerph19116463
Salem Hareedy, M., Mahmoud, W. A., & Tawfik, K. M. (2021). Patterns of thyroid dysfunctions in adolescent patients suffering from severe acne during isotretinoin treatment. Clinical and experimental pharmacology & physiology, 48(10), 1317–1326. https://doi.org/10.1111/1440-1681.13552.
Kotb, M. A., Bin Dayel, S., Abahussein, O., & Hussein, R. S. (2025). Impact of isotretinoin therapy on thyroid hormone levels in acne vulgaris: A prospective study. Medicine, 104(35), e44236. https://doi.org/10.1097/MD.0000000000044236
Yıldırım, N., Doğan, S., & Atakan, N. (2017). Evaluation of thyroid function tests of acne vulgaris patients treated with systemic isotretinoin. The Journal of dermatological treatment, 28(2), 141–144. https://doi.org/10.1080/09546634.2016.1214232
Gencoglan, G., Inanir, I., Miskioglu, M., & Gunduz, K. (2018). Evaluation of sequential effect of isotretinoin on the haematological parameters in patients with acne vulgaris. Cutaneous and ocular toxicology, 37(2), 139–142. https://doi.org/10.1080/15569527.2017.1359837
Ataseven, A., & Ugur Bilgin, A. (2014). Effects of isotretinoin on the platelet counts and the mean platelet volume in patients with acne vulgaris. TheScientificWorldJournal, 2014, 156464. https://doi.org/10.1155/2014/156464
Molina, A. M., van der Mijn, J. C., Christos, P., Wright, J., Thomas, C., Dutcher, J. P., Nanus, D. M., Tagawa, S. T., & Gudas, L. J. (2020). NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. Investigational new drugs, 38(5), 1383–1389. https://doi.org/10.1007/s10637-019-00880-7
Melnik B. C. (2018). Overexpression of p53 explains isotretinoin's teratogenicity. Experimental dermatology, 27(1), 91–93. https://doi.org/10.1111/exd.13420
Altıntaş Aykan, D., & Ergün, Y. (2020). Isotretinoin: Still the cause of anxiety for teratogenicity. Dermatologic therapy, 33(1), e13192. https://doi.org/10.1111/dth.13192
Poinas, A., Lemoigne, M., Le Naour, S., Nguyen, J. M., Schirr-Bonnans, S., Riche, V. P., Vrignaud, F., Machet, L., Claudel, J. P., Leccia, M. T., Hainaut, E., Beneton, N., Dert, C., Boisrobert, A., Flet, L., Chiffoleau, A., Corvec, S., Khammari, A., & Dréno, B. (2020). FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial. Trials, 21(1), 571. https://doi.org/10.1186/s13063-020-04432-w
Views:
69
Downloads:
10
Copyright (c) 2026 Marcin Chwalczuk, Klaudia Leszto, Franciszek Szweda, Tomasz Poczwardowski, Adrianna Kaczmarek, Olivia Grygorcewicz, Marta Koneczna, Katarzyna Anna Kowalska, Jakub Tomasz Latos, Karolina Alicja Krystyniak, Kinga Augustyniak
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
